Sort
130,381 grants matching “hiv”
RAPID SCALE UP FOR HIV CARE AND TREATMENT SERVICES IN NORTHEASTERN
$2,480,000Ahoua Kone · Health Alliance International · U2G · FY2011 · PS
ETIB Clinical Research Core
$2,479,411Ronald Gress · Division Of Basic Sciences - Nci · ZID · FY2011 · CA
PD-1 Function, Signaling, and Regulation During Viral Infection
$2,478,914Rafi Ahmed · Emory University · P01 · FY2009 · AI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine
$2,478,197Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2012 · AI
Vascular Subphenotypes of Lung Disease
$2,477,787Mark Thomas Gladwin · University Of Pittsburgh At Pittsburgh · P01 · FY2014 · HL
TAS::75 0885::TAS NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS
$2,477,572Norman L Letvin · Beth Israel Deaconess Medical Center · N01 · FY2010 · AI
HIV PREVENTION TRIAL UNIT (PRIDE NYC PROGRAM)
$2,477,258Columbia University Health Sciences · U01 · FY2002 · AI
HIV PREVENTION TRIAL UNIT (PRIDE NYC PROGRAM)
$2,476,267Columbia University Health Sciences · U01 · FY2001 · AI
COMBINATION IMMUNIZATION AS AN APPROACH TO AIDS VACCINES
$2,475,278University Of Washington · P01 · FY2000 · AI
Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta
$2,475,013David J Volsky · Icahn School Of Medicine At Mount Sinai · RF1 · FY2022 · NS
University of Pittsburgh Clinical Trials Unit
$2,474,261John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2012 · AI
CCR Genomics Core
$2,473,796Elizabeth Conner · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Single cell determinants of brain in the context of viral persistence in SIV/cART/cocaine non-human primates
$2,473,493Tariq M Rana · University Of California, San Diego · U01 · FY2024 · DA
Clinical Trial Unit for HIV Prevention and Microbicide Research
$2,472,041Kenneth H Mayer · Fenway Community Health Center · U01 · FY2009 · AI
ATN Coordinating Center
$2,471,565Craig M Wilson · University Of Alabama At Birmingham · U01 · FY2006 · HD
Genetic and Biochemical Approaches to Tyrosine Kinase and Lymphocyte Signaling
$2,471,222Pamela Schwartzberg · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Structural and mechanistic studies of herpesvirus entry into host cells
$2,471,000Ekaterina Heldwein · Tufts University Boston · DP2 · FY2007 · OD
THE LEAD PROJECT, LOCAL PARTNERS EXCEL IN COMPREHENSIVE HIV & AIDS SERVICE DELIVE
$2,470,938Mourad Aidi · Catholic Relief Services · U2G · FY2015 · PS
Clinical Development of 4-Cl-KYN to Treat Pain
$2,469,281Ralph Snodgrass · Vistagen Therapeutics, Inc. · R44 · FY2009 · DA
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders
$2,469,009Brian P Sorrentino · St. Jude Children'S Research Hospital · P01 · FY2010 · HL
Pitt-Ohio State Clinical Trials Unit
$2,468,833John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2023 · AI
Single cell determinants of brain in the context of viral persistence in SIV/cART/cocaine non-human primates
$2,467,417Tariq M Rana · University Of California, San Diego · U01 · FY2025 · DA
Measurement of HIV Neutralization Using Quantitative Assays
$2,467,107John Mascola · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
RNA INTERFERENCE AS A WEAPON AGAINST BIOTERRORISM
$2,467,065Immune Disease Institute, Inc. · U19 · FY2004 · AI
UNIVERSIDAD CENTRAL DEL CARIBE BIOMEDICAL RESEARCH CENTERS
$2,466,296Jose Ginel Rodriguez · Universidad Central Del Caribe · G12 · FY2011 · RR